Dr. Mark Lemmon

Biography

Mark Lemmon is the Alfred Gilman Professor of Pharmacology and Co-Director of the Yale Cancer Biology Institute. He has been a faculty member for 19 years at the University of Pennsylvania’s Perelman School of Medicine, where he held the George W. Raiziss Professorship in Biochemistry and Biophysics and chaired the department while contributing to the Abramson Family Cancer Research Institute. In 2016, he was elected a Fellow of the Royal Society. Dr. Lemmon's research investigates the signaling networks controlled by receptor tyrosine kinases (RTKs) and growth factors that are mutated in various cancers. By combining biochemical, structural, and cellular approaches, his lab aims to decode the mechanisms of RTK signaling, which is essential for developing targeted therapies. His work on the Epidermal Growth Factor Receptor (EGFR) has significantly enhanced the understanding of its activation mechanisms and therapeutic implications. In addition to EGFR, his research encompasses the study of RTKs involved in immune cell regulation and signaling pathways associated with cancer. Dr. Lemmon's professional contributions also include editorial responsibilities with leading journals in the field.

Research Interests